Company news

Aquestive Therapeutics, Inc. news in 2021

Aquestive Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film

December 19, 2021

Aquestive Therapeutics Added to NASDAQ Biotechnology Index

December 16, 2021

Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)

December 12, 2021

Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

November 16, 2021

Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance

November 1, 2021

Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of All...

October 24, 2021

Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8: 00 a.m. ET

October 13, 2021

Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement

October 5, 2021

IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U.S.

September 28, 2021

Aquestive Therapeutics to Participate in Three Investor Conferences in September

September 6, 2021

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement

August 8, 2021

Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference

August 5, 2021

Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance

August 2, 2021

Aquestive Therapeutics to Report Second Quarter 2021 Financial Results and Recent Business Highlights on August 3 and Host Conference Call on August 4 at 8: 00 a.m. ET

July 20, 2021

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film

July 18, 2021

Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film

June 23, 2021

Aquestive Therapeutics Announces Leadership Transition of Chief Financial Officer

June 20, 2021

Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences

June 8, 2021

Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference

May 10, 2021

Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021

Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8: 00 a.m. ET

April 20, 2021

Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine

March 24, 2021

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

March 8, 2021

Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9: 00 a.m. ET

March 4, 2021

Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback

February 24, 2021

Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8: 00 a.m. ET

February 16, 2021

Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

February 8, 2021

Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy

January 27, 2021

Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

January 20, 2021

Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

January 3, 2021

Calls in 2021

Decks in 2021